{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:54:22Z","timestamp":1773341662288,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF) that has been used as a systemic chemotherapy treatment of various malignancies in adults since 2000. It has been used for pediatric patients over the last decade. In addition, bevacizumab is used for neonatal intravitreal administration for retinopathy of prematurity, a major complication of preterm birth, characterized by incomplete and abnormal vascularization of the retina that can lead to retinal detachment and blindness without treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CASES:<\/jats:title>\n            <jats:p>The objective of this multiple case series is to report impaired wound healing seen in 3 adolescents and 1 premature neonate receiving bevacizumab and to propose collagen-based dermal template as a choice for the management of such wounds. The 3 adolescents were undergoing treatment of malignancies and developed wound healing complication within weeks of receiving anti-VEGF. The premature neonate experienced an extravasation and had a slow wound healing trajectory after receiving intravitreal administration of bevacizumab for retinopathy of prematurity. All wounds achieved closure following topical treatment with a collagen dermal template.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Use of bevacizumab is increasing in the pediatric population. Clinicians should be aware of compromised wound healing and higher likelihood of wound dehiscence after bevacizumab administration. We recommend waiting for at least 4 to 6 weeks between anti-VEGF administration (either systemic or vitreous) and elective surgical procedures, consistent with adult literature recommendations. If patient has an existing wound, we assert that bevacizumab should not be administered until that wound is healed. If wound healing is stalled, we recommend dermal template as a safe and effective accelerator of wound healing.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/won.0000000000000764","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T10:46:49Z","timestamp":1620384409000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Association of Systemic or Intravitreal Antivascular Endothelial Growth Factor (Anti-VEGF) and Impaired Wound Healing in Pediatric Patients"],"prefix":"10.1097","volume":"48","author":[{"given":"Vita","family":"Boyar","sequence":"first","affiliation":[{"name":"Vita Boyar, MD,Steven & Alexandra Cohen Children's Medical Center, New Hyde Park, New York; and Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"6","key":"R1-20250806","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"issue":"9","key":"R2-20250806","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00129334-200511000-00013","article-title":"The role of therapeutic angiogenesis in tissue repair and regeneration","volume":"18","author":"Li","year":"2005","journal-title":"Adv Skin Wound Care"},{"issue":"7","key":"R3-20250806","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"R4-20250806","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravenous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"2985161","DOI":"10.1155\/2019\/2985161","article-title":"Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity","volume":"2019","author":"Chen","year":"2019","journal-title":"J Ophthalmol"},{"issue":"4","key":"R6-20250806","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iwj.13139","article-title":"Impaired wound healing secondary to bevacizumab","volume":"16","author":"Ahn","year":"2019","journal-title":"Int Wound J"},{"issue":"4","key":"R7-20250806","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SAP.0b013e31824e5e57","article-title":"Bevacizumab and wound healing complications: mechanism of action, clinical evidence, and management recommendations for the plastic surgeon","volume":"71","author":"Sharma","year":"2013","journal-title":"Ann Plastic Surg"},{"issue":"10","key":"R8-20250806","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM199909023411006","article-title":"Cutaneous wound healing","volume":"341","author":"Singer","year":"1999","journal-title":"N Engl J Med"},{"issue":"21","key":"R9-20250806","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/ajhp\/61.suppl_5.S21","article-title":"Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor","volume":"61","author":"Ignoffo","year":"2004","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"R10-20250806","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1534734603256626","article-title":"The role of vascular endothelial growth factor in wound healing","volume":"2","author":"Bates","year":"2003","journal-title":"Int J Low Extremity Wounds"},{"issue":"3","key":"R11-20250806","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"issue":"20","key":"R12-20250806","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","article-title":"Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"R13-20250806","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"issue":"6","key":"R14-20250806","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3171\/2010.10.JNS101042","article-title":"Impact of bevacizumab chemotherapy on craniotomy wound healing","volume":"114","author":"Clark","year":"2011","journal-title":"J Neurosurg"},{"issue":"3","key":"R15-20250806","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1245\/s10434-010-1366-8","article-title":"Does neoadjuvant bevacizumab increase surgical complications in breast surgery?","volume":"18","author":"Golshan","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"R16-20250806","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma","volume":"27","author":"Jonasch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vph.2018.10.005","article-title":"Beyond endothelial cells: vascular endothelial growth factors in heart, vascular anomalies and placenta","volume":"112","author":"Laakkonen","year":"2019","journal-title":"Vasc Pharmacol"},{"issue":"10","key":"R18-20250806","doi-asserted-by":"crossref","first-page":"e0223972","DOI":"10.1371\/journal.pone.0223972","article-title":"Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"R19-20250806","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"R20-20250806","doi-asserted-by":"crossref","first-page":"e20191814","DOI":"10.1542\/peds.2019-1814","article-title":"Hypertension and neuroimaging changes after bevacizumab for retinopathy of prematurity","volume":"145","author":"Twitty","year":"2020","journal-title":"Pediatrics"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/OPTH.S40537","article-title":"The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing","volume":"7","author":"Christoforidis","year":"2013","journal-title":"Clin Ophtalmol"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/OPTH.S28275","article-title":"The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model","volume":"6","author":"Christoforidis","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"R23-20250806","first-page":"347","article-title":"A review of collagen and collagen-based wound dressings","volume":"20","author":"Brett","year":"2008","journal-title":"Wounds"},{"issue":"3","key":"R24-20250806","first-page":"50","article-title":"Modern collagen wound dressing; function and purpose","volume":"2","author":"Fleck","year":"2010","journal-title":"J Am Col Certif Wound Spec"},{"issue":"10","key":"R25-20250806","first-page":"8","article-title":"Complex problem, simple solution: using Endoform to provide a functional extracellular matrix in chronic wounds","volume":"65","author":"Bohn","year":"2019","journal-title":"Wound Manag Prev"}],"container-title":["Journal of Wound, Ostomy &amp; Continence Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WON.0000000000000764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:00:17Z","timestamp":1754492417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/WON.0000000000000764"}},"subtitle":["Collagen to the Rescue"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/won.0000000000000764","relation":{},"ISSN":["1071-5754"],"issn-type":[{"value":"1071-5754","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}